Healthpeak Properties (DOC) was recently added to both the Russell 2500 Index and the Russell 2500 Value Benchmark. This type of inclusion can influence trading activity as index-tracking investors adjust their portfolios.

Healthpeak Properties' recent index additions come after a strong run in the share price, with a 30-day share price return of 13.89% and a 90-day share price return of 30.99%. However, the 5-year total shareholder return of 16.79% indicates that longer term performance has been weaker.

If this kind of index driven interest has you looking beyond a single REIT, it could be a good moment to broaden your search with the 20 top founder-led companies

With Healthpeak Properties now in key Russell indices, a 42% implied intrinsic discount and recent share price strength, the real question for investors is whether there is still an opportunity here or if markets are already accounting for potential future growth.

Most Popular Narrative: 1% Overvalued

Healthpeak Properties is trading at $21.64, just above the narrative fair value of $21.44, which reflects detailed assumptions about future revenues, margins and required returns.

The analysts have a consensus price target of $21.44 for Healthpeak Properties based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $29.0, and the most bearish reporting a price target of just $17.0.

Want to see what sits behind that tight fair value range? The narrative leans on modest revenue growth, thinner margins, and a relatively rich future earnings multiple that is far from ordinary.

Result: Fair Value of $21.44 (ABOUT RIGHT)

However, Healthpeak Properties still faces concentration and refinancing risks, where tenant stress or tighter capital markets could pressure rental income, margins and future flexibility.

Another View on Healthpeak Properties Valuation

While the analyst narrative points to Healthpeak Properties trading around fair value at $21.64 versus a $21.44 target, the SWS DCF model presents a different perspective and suggests the stock is trading below an estimated future cash flow value of $37.51. Which lens do you trust more when cash flows and multiples disagree?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Healthpeak Properties for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 41 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the split sentiment around Healthpeak Properties has you on the fence, check the data, weigh the trade offs, and make your own call with 1 key reward and 4 important warning signs

Looking for more investment ideas beyond Healthpeak Properties?

Healthpeak Properties may give you a clear reference point, but the real edge often comes from lining it up against a wider set of quality opportunities.

• Target income strength by reviewing companies in the 8 dividend fortresses and see which ones could complement a REIT like Healthpeak Properties in a portfolio.
• Hunt for potential mispricings with the 41 high quality undervalued stocks to compare how other stocks stack up against Healthpeak Properties on quality and price.
• Prioritise resilience by screening for companies in the 73 resilient stocks with low risk scores that might help balance out any single stock or sector exposure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.